KOSDAQBiotech & Pharma002800

Sinsin Pharmaceutical

₩3,780▲ 0.80%2026-11-18 close
Market Cap
₩57.3B
Turnover
₩61,674,210
Volume
20K
Shares out.
15.2M
PER
6.0×
PBR
0.8×
EPS
₩648
Dividend Yield
2.06%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩80 per share · Prices as of the 2026-11-18 close

01

Report overview

Patch-Driven Margin Gains; Q3 2026 Net Loss Under Review

Sinsin Pharmaceutical lifted its operating margin to 9.5% in 2025 on its patch franchise, but a Q3 2026 net loss attributable to controlling shareholders makes earnings durability the next test.

  1. 1

    Operating profit reached KRW 10.8 billion in 2025, up 56.6% year on year, and the operating margin rose to 9.5% from 5.9% in 2022.

  2. 2

    Q3 2026 revenue was KRW 34.2 billion, rising for three consecutive quarters from Q1 2026, but the company swung to a net loss attributable to controlling shareholders of KRW 223 million.

  3. 3

    Patches accounted for 53.4% of Q1 2026 revenue, and pharmacies were the largest sales channel at 48.1%.

  4. 4

    Total equity stood at KRW 74.5 billion at end-2025, and the debt ratio fell to 84.5% from 103.6% in 2022.

  5. 5

    The next checkpoints are the 2026 annual report, due by the end of March 2027, and the progress of the UIP-620 Phase 3 trial.

02

Business structure

Sinsin Pharmaceutical was founded in 1959 as a domestic maker of finished pharmaceuticals, and its core business is patch products built on its transdermal drug delivery system (TDDS) technology.

According to a report citing a regulatory filing, patches generated about 57.06% of 2025 sales, and most of the remaining major revenue also comes from over-the-counter (OTC) products.

By dosage form, Q1 2026 revenue of KRW 30.2 billion was led by patches at KRW 16.1 billion, or 53.4%, followed by topical solutions at 16.6%, oral drugs at 11.1%, ointments at 7.5% and aerosols at 4.2%.

By sales channel, pharmacies were the largest at 48.1%, followed by pharmaceutical wholesalers at 22.8% and distribution vendors at 13.3%. Export sales in the same quarter were KRW 4.4 billion, or 14.5% of the total, with Southeast Asia, Asia and Europe named as the main export regions.

The company highlights its direct-trade network with about 13,000 retail pharmacies nationwide. Its flagship Arex brand and related products drove the recent revenue gains. Production is handled mainly at the Sejong plant, which began operating in 2019, and patch lines account for a large share of that plant.

A trade report put the patch line utilization rate at around 98% on a cumulative basis through Q3 2025. Competitively, domestic patches are seen as offering more variety and efficacy than Chinese patches, but domestic OTC market growth potential is viewed as limited.

Related parties of the largest shareholder held 51.50% as of September 10, 2026, concentrating management control.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩30.1B₩4B13.1%
2025Q4₩28.8B₩3.3B11.6%
2026Q1₩30.2B₩3.2B10.5%
2026Q2₩34B₩4.1B12.0%
2026Q3₩34.2B₩4.3B12.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩91.9B₩5.4B₩4.4B5.9%7.4%103.6%
2023₩102.6B₩6B₩4.7B5.9%7.5%100.4%
2024₩106.4B₩6.9B₩4.9B6.5%7.4%97.5%
2025₩113.8B₩10.8B₩9.3B9.5%12.4%84.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a filed basis, annual revenue was KRW 91.9 billion in 2022, KRW 102.6 billion in 2023 (up 11.6% year on year), KRW 106.4 billion in 2024 (up 3.7%) and KRW 113.8 billion in 2025 (up 6.9%).

Revenue rose for three consecutive years from 2023 to 2025, with 2025 the largest year and 2022 the smallest in the 2022-2025 span. Operating profit climbed from KRW 5.43 billion in 2022 to KRW 6 billion in 2023 and KRW 6.89 billion in 2024, then reached KRW 10.8 billion in 2025 (up 56.6%).

The operating margin moved from 5.9% in 2022 and 5.9% in 2023 to 6.5% in 2024 and 9.5% in 2025. Revenue grew 6.9% in 2025 while operating profit grew 56.6%, which points to cost-ratio improvement rather than volume alone.

Press reports credited automation and process upgrades at the Sejong plant, operating since 2019, as the main driver of the profit structure change. Profit attributable to controlling shareholders rose from KRW 4.41 billion in 2022 to KRW 4.68 billion, KRW 4.89 billion and KRW 9.29 billion in 2025 (up 90.1%).

Reports said non-operating income, including Sejong city employment incentives, contributed to the 2025 net income gain, so whether that recurs will become clearer from the non-operating items in upcoming annual reports.

Quarterly revenue fell from KRW 30.1 billion in Q3 2025 to KRW 28.8 billion in Q4 2025, then rose to KRW 30.2 billion, KRW 34 billion and KRW 34.2 billion across Q1 to Q3 2026.

Operating profit bottomed at KRW 3.18 billion in Q1 2026 and then rose to KRW 4.06 billion and KRW 4.28 billion, the latter up 8.1% year on year.

Even so, Q3 2026 produced a net loss attributable to controlling shareholders of KRW 223 million, so the gap between higher operating profit and a net loss makes non-operating items and income tax the key lines to watch.

Profit attributable to controlling shareholders over the last four quarters totaled KRW 9.82 billion. Operating cash flow was KRW 5.46 billion in 2022, KRW 3.93 billion in 2023, KRW 5.94 billion in 2024 and KRW 8.58 billion in 2025.

05

Industry analysis

Both the company and the industry expect patch demand to grow as Korea ages. Many observers, however, see limited growth potential in the domestic OTC market, and analysts argue that overseas expansion is needed for top-line growth. A 2024 report said exports had risen more than 43% over the prior two years.

In China, the company agreed with Sinopharm to supply 12 products through Alibaba's online store over five years, for a total of about USD 5.4 million, according to a 2024 report. Press coverage noted that China's sanitary permit process is demanding and raises the entry barrier.

On product competitiveness, domestic patches are viewed as offering more variety and better efficacy than Chinese patches. OTC-focused drugmakers have traditionally been viewed as low-margin businesses, and Sinsin's operating margin in the 9% range has been reported as departing from that pattern.

In microneedle drug delivery, no domestic commercial precedent yet exists, and the company aims to be the first to commercialize one in Korea. Large drugmakers' Q3 2026 results also diverged based on new drug and export performance, so portfolio diversification is a shared industry challenge.

06

Outlook

The core of the new drug pipeline is UIP-620, a transdermal improved new drug for overactive bladder. In a 2024 report, the company said it aimed to enter a domestic Phase 3 trial and commercialize within two to three years, with the trial planned for 500 patients at about ten domestic hospitals.

The same report cited industry expectations of commercialization around 2026 if Phase 3 started, but that timeline depends on trial progress, so the latest stage should be confirmed through company disclosures.

A second candidate, SS-262, is being developed as a transdermal insomnia treatment, and a domestic Phase 1 trial plan had been filed.

The company said it completed non-clinical testing of its microneedle drug in April 2025 and is pursuing rapid approval from the drug regulator through production process setup and equivalence testing. After approval, it plans to review investment in GMP-compliant production equipment.

On the commercial side, an October 2026 report described a supply agreement giving exclusive sales rights to nine products across six OTC brands through 2028, extending the pharmacy network into a wider product range.

Chairman Lee Byeong-gi said in his New Year message that growth would center on patches and be performance-based rather than expansion for its own sake. Overseas, the plan is to widen export countries from China online sales to Central Asia, Indonesia and Latin America.

R&D spending rose from about KRW 1.4 billion in 2022 to KRW 1.9 billion in 2023 and KRW 2.3 billion in 2024, and whether it translates into new drug results will show up in clinical disclosures and changes in the sales mix.

07

Valuation

PER
6.0×
PBR
0.8×
ROE
13.1%
EPS
₩648
BPS
₩5,181
Dividend per share
₩80

The price-to-book ratio sits below 1x, meaning the share price is trading under book value per share. Equity expanded from the mid-KRW 65 billion range at end-2024 to KRW 74.5 billion at end-2025, while the debt ratio fell from 97.5% to 84.5% over the same period.

Earnings-based multiples should be read against profit attributable to controlling shareholders over the last four quarters, which totaled KRW 9.82 billion, and that base now includes the Q3 2026 net loss, so such multiples can shift sharply from quarter to quarter.

Because 2025 net income included non-operating income, earnings-based multiples are easier to interpret alongside operating-profit-based measures. Dividend yield moves with earnings and payout policy, so it should be read together with whether annual earnings recover.

Comparing the current level with past trading ranges requires checking brokerage valuation band data or exchange records directly.

The rise in operating margin from 5.9% in 2022 to 9.5% in 2025 documents a change in the profit structure, and how multiples are read depends on whether that change carries through into quarterly results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Structural margin improvement

The operating margin rose from 5.9% in 2022 to 9.5% in 2025, and automation and process upgrades at the Sejong plant are cited as cost-ratio drivers. Operating profit rose in Q2 and Q3 2026 after the Q1 low, so the quarterly trend also points upward. A trade report cited patch line utilization near 98% through Q3 2025, indicating high production efficiency.

Revenue momentum and export expansion

Revenue rose for three consecutive quarters from Q1 to Q3 2026, and Q3 revenue of KRW 34.2 billion was up 13.4% year on year. Export sales were KRW 4.4 billion in Q1 2026, or 14.5% of the total, and overseas channels are widening through China online sales. Product expansion, such as the exclusive OTC supply agreement, adds another growth lever.

Easing financial burden

The debt ratio fell from 103.6% in 2022 to 84.5% in 2025, and total equity stood at KRW 74.5 billion at end-2025. Operating cash flow grew from KRW 5.46 billion in 2022 to KRW 8.58 billion in 2025, meaning more cash came from core operations. Rising equity widens financial room for new drug and microneedle investment.

09

Bear factors

Swing to a Q3 net loss

Q3 2026 operating profit rose to KRW 4.28 billion year on year, yet profit attributable to controlling shareholders swung to a net loss of KRW 223 million. The widening gap between operating and net results suggests greater volatility in non-operating or tax items. Because 2025 net income also included non-operating income, more evidence is needed on earnings quality.

Growth limits of a domestic-centric model

Domestic sales accounted for 86% of revenue in 2023, and pharmacies and wholesalers still dominate sales in Q1 2026. Many observers see limited growth in the domestic OTC market, so top-line expansion depends on overseas sales. Exports were 14.5% of revenue in Q1 2026, so overseas sales are not yet large enough to carry overall growth.

Uncertain payoff from new drugs

UIP-620 Phase 3 entry was a within-the-year target in a 2024 report, but trial timing can shift against company disclosures. R&D spending rose to KRW 1.9 billion in 2023 and KRW 2.3 billion in 2024, so the cost of new drug development is already flowing through expenses. Related parties of the largest shareholder hold 51.50%, which concentrates control.

10

Risk factors

Product concentration and pricing pressure

Patches generated about 57.06% of 2025 sales, so dependence on a single dosage form is high. Most remaining revenue also comes from OTC products, which exposes the company to shifts in that market. Generic products face pricing pressure, so the pace of product mix change matters.

Quarterly earnings volatility

Q1 2026 operating profit hit a low of KRW 3.18 billion, and Q3 brought a net loss attributable to controlling shareholders. Reports said non-operating income partly contributed to 2025 net income. Quarterly swings are large, so one or two quarters make trend assessment difficult.

Execution risk in overseas and new businesses

Export sales were KRW 4.4 billion in Q1 2026, or 14.5% of revenue, and China entry is at an early stage through online sales. Microneedle approval and new drug trials are long-term tasks where timelines can slip. If new business spending hits costs first, short-term profitability could come under pressure.

11

What to watch next

  1. Early February 2027 (based on last year's preliminary disclosure timing)

    Check whether the full-year 2026 preliminary results keep the operating margin near the 9.5% level of 2025, and whether annual revenue exceeds KRW 113.8 billion.

  2. By end-March 2027 (annual report filing deadline)

    The 2026 annual report will show Q4 results, non-operating items and tax structure, clarifying the cause of the Q3 net loss and whether non-operating income recurs.

  3. By May 15, 2027 (Q1 2027 quarterly report filing deadline)

    Check whether Q1 2027 revenue exceeds the KRW 30.2 billion of Q1 2026, whether operating profit recovers from the KRW 3.18 billion low, and whether net profit returns to positive territory.

  4. Timing unscheduled (company disclosure dependent)

    Watch for disclosure of UIP-620 Phase 3 entry and the filing or approval status of the microneedle drug with the drug regulator. These events indicate when the new drug revenue mix could begin to change.

12

Overall view

Sinsin Pharmaceutical raised its operating margin from 5.9% in 2022 to 9.5% in 2025 on a patch and OTC-centered model, and 2025 operating profit of KRW 10.8 billion was up 56.6% year on year.

Revenue, operating profit and profit attributable to controlling shareholders rose for three consecutive years from 2023 to 2025, and the balance sheet improved with a debt ratio of 84.5% and equity of KRW 74.5 billion.

In 2026, revenue rose for three consecutive quarters from KRW 30.2 billion in Q1 to KRW 34.2 billion in Q3, and operating profit increased for two consecutive quarters after Q1.

However, the Q3 2026 net loss attributable to controlling shareholders of KRW 223 million makes whether operating gains carry through to net profit the central open question. Patches account for more than half of revenue, and limited domestic OTC growth is a structural challenge.

Exports were 14.5% of revenue, and UIP-620 and the microneedle drug remain in clinical or approval stages, so the timing of their payoff is uncertain.

Structural margin gains and quarterly earnings volatility coexist, and the next checkpoints are the operating margin and non-operating items in the 2026 annual report and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. dailypharm.com
  3. news.g-enews.com
  4. kr.investing.com
  5. thebionews.net
  6. kpanews.co.kr
  7. medicaltimes.com
  8. pharm.edaily.co.kr
  9. paxetv.com
  10. greened.kr
  11. edaily.co.kr
  12. edaily.co.kr
  13. news.bizwatch.co.kr
  14. asiatime.co.kr
  15. kr.investing.com
  16. jobkorea.co.kr
  17. medicopharma.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis